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Abstract
TMPRSS2–ERG gene fusions are the predominant molecular subtype of prostate cancer. Here, we explored the role of
TMPRSS2–ERG gene fusion product using in vitro and in vivo model systems. Transgenic mice expressing the ERG gene
fusion product under androgen-regulation develop mouse prostatic intraepithelial neoplasia (PIN), a precursor lesion of pros-
tate cancer. Introduction of the ERG gene fusion product into primary or immortalized benign prostate epithelial cells induced
an invasion-associated transcriptional program but did not increase cellular proliferation or anchorage-independent growth.
These results suggest that TMPRSS2–ERGmay not be sufficient for transformation in the absence of secondary molecular
lesions. Transcriptional profiling of ERG knockdown in the TMPPRSS2–ERG–positive prostate cancer cell line VCaP revealed
decreasedexpression of genesover-expressed in prostate cancer versusPIN andgenes overexpressed in ETS-positive versus
-negative prostate cancers in addition to inhibiting invasion. ERG knockdown in VCaP cells also induced a transcriptional pro-
gram consistent with prostate differentiation. Importantly, VCaP cells and benign prostate cells overexpressing ERG directly
engage components of the plasminogen activation pathway to mediate cellular invasion, potentially representing a down-
stream ETS target susceptible to therapeutic intervention. Our results support previous work suggesting that TMPRSS2–
ERG fusions mediate invasion, consistent with the defining histologic distinction between PIN and prostate cancer.
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Introduction
Based on a bioinformatics strategy that nominated genes showing
high expression in a subset of cancer cases, we identified fusions of
the 5′-untranslated region of TMPRSS2 (21q22) to ERG (21q22),
ETV1 (7p21), ETV4 (17q21), or ETV5 (3q27) in prostate cancer
cases that over-expressed the respective ETS family member [1–3].
TMPRSS2–ERG fusions are the most predominant molecular sub-
type, with multiple studies showing that approximately 50% of pros-
tate cancers from prostate-specific antigen (PSA) screened surgical
cohorts are TMPRSS2–ERG fusion-positive, and greater than 90%
of prostate cancers over-expressing ERG harbor TMPRSS2–ERG fu-
sions [2,4–18].
As TMPRSS2 had previously been characterized as an androgen-
regulated gene [19], and TMPRSS2 only contributes untranslated se-
quence to many TMPRSS2–ERG transcripts, we hypothesized that
the androgen responsive regulatory elements of TMPRSS2 drive
ERG over-expression in fusion-positive cases. In support of this hy-
pothesis, we observed that treatment of the TMPRSS2–ERG–positive
prostate cancer cell line VCaP with the synthetic androgen R1881
resulted in increased expression of the TMPRSS2–ERG [2,20] fusion
product. Additionally, castration of mice with androgen-dependent
TMPRSS2–ERG–positive xenografts resulted in decreased expression
of ERG in the xenograft [21].
Following the identification of TMPRSS2 fusions to ERG, ETV1,
and ETV4, we recently discovered additional 5′ fusion partners in-
volved in ETV1 and ETV5 gene fusions, including the 5′ untranslated
regions from SLC45A3, HERV–K_22q11.3, C15ORF21, and
HNRPA2B1 [3,22]. Presently, these additional 5′ partners have only
been identified in ETV1 and ETV5 fusions, and it is unknown if they
can fuse with ERG (in rare TMPRSS2–ERG–negative cases with ERG
outlier expression) or additional ETS family members. ETV1 and
ETV5 gene fusions are relatively rare and account for only 2% to
8% of prostate cancers. Interestingly, in these recent studies, we ob-
served that ETV1 or ETV5 over-expression induces a cell invasion pro-
gram [3,22]. Furthermore, androgen regulation and over-expression of
the ETV1 fusion product in the prostate induced mouse prostatic intra-
epithelial neoplasia (mPIN) in mice. Thus, whereas ETV1 and ETV5
are rare gene fusions in prostate cancer, it is unknown if the functional
role of the most common aberration in prostate cancer, TMPRSS2–
ERG, is similar. Here, we recapitulated TMPRSS2–ERG fusions in vivo
and in vitro and used an integrative expression profiling strategy to de-
termine functional roles for TMPRSS2–ERG in prostate cancer.
Materials and Methods
Transgenic ERG Mice
cDNA of ERG (exon 2 to base 1533 of NM_182918.2), was am-
plified by reverse transcription–polymerase chain reaction (RT-PCR)
from the VCaP cell line and TOPO cloned into the Gateway entry
vector pCR8/GW/TOPO (Invitrogen, Carlsbad, CA), yielding
pCR8-ERG. 3XFLAG-epitope–tagged construct was generated by
PCR using pCR8-ERG as the template with the reverse primer en-
coding a triple FLAG tag before the stop codon. The product was
TOPO cloned into pCR8, generating pCR8-3xFLAG-ERG. To
generate a prostate-specific ERG transgenic construct, 3xFLAG-
ERG was inserted into pBSII (Stratagene, La Jolla, CA) downstream
of a modified small composite probasin promoter (ARR2PB) and up-
stream of a bovine growth hormone polyA site (PA-BGH) [23,24].
The ARR2Pb-ERG plasmid was linearized with PvuI/KpnI/SacII and
microinjected into fertilized FVB mouse eggs and surgically trans-
planted into a pseudopregnant female by the University of Michigan
Transgenic Animal Model Core. Transgenic founders were screened
by PCR using genomic DNA isolated from tail snips. Multiple
ARR2Pb-ERG transgenic founders were obtained and crossed with
FVB mice, and transgene-positive male mice offspring were sacrificed
at various time points.
Prostates from transgenic mice were dissected, stained with hema-
toxylin and eosin, and evaluated by three pathologists (R.M., M.A.R.,
and R.B.S.) as described earlier [22,25].
For immunohistochemical detection of Erg-FLAG, the basal cell
marker p63, and smooth muscle actin, deparaffinized slides were sub-
jected to microwave-citrate antigen retrieval and incubated with rabbit
anti–FLAG polyclonal antibody (1:50 dilution, overnight incubation,
#2368; Cell Signaling Technology, Danvers, MA), mouse monoclo-
nal anti–p63 antibody (1:100 dilution, 45 minutes of incubation,
MS1081P1; LabVision, Fremont, CA), and mouse monoclonal anti–
smooth muscle actin antibody (1:50 dilution, 30 minutes of incuba-
tion, M0851; DakoAb, Carpinteria, CA), respectively. Visualization of
p63 and SMA was performed using a standard biotin–avidin complex
technique using M.O.M. Immunodetection kit (PK2200; Vector Lab-
oratories, Burlingame, CA). FLAG was detected using Envision+System–
HRP (DAB) kit (K4011; DakoCytomation, Carpinteria, CA).
Cell Lines and Samples
The benign immortalized prostate cell line RWPE was obtained
from the American Type Culture Collection (Manassas, VA). Primary
benign prostatic epithelial cells (PrEC) were obtained from Cambrex
Bio Science (Walkersville, MD). VCaP was derived from a vertebral
metastasis from a patient with hormone-refractory metastatic pros-
tate cancer [26], and was provided by Kenneth Pienta (University
of Michigan).
Prostate tissues were from the radical prostatectomy series at the
University of Michigan and from the Rapid Autopsy Program, which
are both part of the University of Michigan Prostate Cancer Spe-
cialized Program of Research Excellence Tissue Core. All samples
were collected with informed consent of the patients and prior insti-
tutional review board approval. For all samples and cell lines, total
RNA was isolated with Trizol (Invitrogen) according to the manufac-
turer’s instructions.
In Vitro Over-expression of ERG
To generate adenoviral and lentiviral constructs, pCR8-ERG and
a control entry clone (pENTR-GUS) were recombined with pAD/
CMV/V5 (Invitrogen) and pLenti6/CMV/V5 (Invitrogen), respec-
tively, using LR Clonase II (Invitrogen). Control pAD/CMV/LACZ
clones were obtained from Invitrogen. Adenoviruses and lentiviruses
were generated by the University of Michigan Vector Core. The be-
nign immortalized prostate cell line RWPE was infected with lenti-
viruses expressing ERG or GUS, and stable clones were generated by
selection with blasticidin (Invitrogen). Benign PrEC cells were infected
with adenoviruses expressing ERG or LACZ. RWPE cells were also in-
fected with ERG or LACZ adenoviruses for transient over-expression.
Immunoblot Analysis
Cell lysates transferred to polyvinylidene fluoride membranes were
probed with rabbit polyclonal anti-ERG (sc-354; Santa Cruz Bio-
technology, Santa Cruz, CA) at 1:500 dilution, mouse monoclonal
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anti–matrix metalloproteinase 3 (MMP3) (IM36L; Calbiochem, San
Diego, CA) at 1:500 dilution, mouse monoclonal anti-uPA (IM13L,
Calbiochem) at 1:500 dilution, and mouse anti–GAPDH antibody
(Abcam, Cambridge, MA) at 1:30,000 dilution for loading control.
Proliferation Assay
Cell counts were estimated by trypsinizing the cells and, analysis
was done using a Coulter counter (Beckman Coulter, Fullerton, CA)
at the indicated time points in triplicate.
FACS Cell Cycle Analysis
Propidium iodide–stained RWPE-ERG and RWPE-GUS cells
were analyzed on a LSR II flow cytometer (BD Biosciences, San Jose,
CA) running FACSDivia, and cell cycle phases were calculated using
ModFit LT (Verity Software House, Topsham, ME).
Soft Agar Assay
A 0.6% (wt./vol.) bottom layer of low melting point agarose in
normal medium was prepared in six-well culture plates. On top, a
layer of 0.3% agarose containing 1 × 104 RWPE-GUS, RWPE-
ERG, or DU145 (positive control) cells was placed. After 12 days,
foci were stained with crystal violet and counted.
Invasion Assays
Invasion assays were performed using PrEC and RWPE-ERG and
-LACZ cells (48 hours after infection with adenoviruses), stable
RWPE-ERG and -GUS cells, or VCaP cells as described earlier [22].
For inhibitor studies, amiloride (20 μM; EMD Biosciences, San
Diego, CA), MMP3 inhibitor (10 μM; EMD Biosciences),
MMP2/9 inhibitor (10 μM; EMD Biosciences), MMP8 inhibitor
(10 μM; EMD Biosciences), the pan MMP inhibitor GM 6001
(10 μM; EMD Biosciences), the EWS:FLI inhibitor cytosine arabi-
noside (250 nM) [27], or vehicle control was added to VCaP and
stable RWPE-ERG or -GUS cells for 24 hours, before trypsinization
and seeding for invasion assays. For PAI-1, VCaP and stable RWPE-
ERG or -GUS cells were trypsinized and treated with the indicated
amount of recombinant PAI-1 (EMD Biosciences) for 15 minutes at
indicated concentrations, before seeding.
ERG, PLAU, and PLAT Knockdown
For short interfering RNA (siRNA) knockdown of ERG, PLAT, or
PLAU, the individual siRNA composed of the Dharmacon SMART-
pool against ERG (MQ-003886-01; Lafayette, CO), PLAT (LQ-
005999-00), or PLAU (LQ-006000-00), were tested for knockdown
by quantitative polymerase chain reaction (qPCR), and the most ef-
fective single siRNA (ERG, D-003886-01; PLAT, J-005999-05;
PLAU, J-006000-07) was used for further experiments. siCONTROL
Non-Targeting siRNA #1 (D-001210-01) or siRNA against ERG,
PLAT, or PLAU was transfected into VCaP or RWPE-ERG cells as in-
dicated using Oligofectamine (Invitrogen). After 24 hours, we carried
out a second identical transfection and cells were harvested 24 hours
later for RNA isolation, invasion assays, or proliferation assays.
Expression Profiling
Expression profiling was performed using the Agilent Whole Hu-
man Genome Oligo Microarray (Santa Clara, CA) according to the
manufacturer’s protocol [22]. For all hybridizations involving ERG
over-expression by adenovirus or lentivirus, the reference was the
same cell line expressing LACZ or GUS, respectively. For profiling
of ERG knockdown in VCaP, the reference was VCaP treated with
nontargeting siRNA. All hybridizations were performed in duplicate
with duplicate dye flips, for a total of four arrays, except for tran-
siently expressing RWPE-ERG, which consisted of duplicate hybridi-
zations and a single dye flip. Over- and under-expressed signatures
were generated by filtering to include only features with significant
differential expression (Log ratio, P < .01) in all hybridizations and
two-fold average over- or under-expression (Log ratio) after correc-
tion for the dye flip. For VCaP profiling, all features with significant
differential expression (Log ratio, P < .01) and Cy5/Cy3 ratios of >
or < 1 in all hybridizations were included in the over- and under-
expressed signatures, respectively.
Molecular Concepts Analysis
All expression signatures were uploaded into the Oncomine Con-
cepts Map (OCM, www.oncomine.org) [28] as molecular concepts,
using all features on the Agilent Whole Human Genome Oligo Mi-
croarray as the null set. For the assessment of prostate-specific gene
expression, the expO (GSE2109) and Shyamsundar normal tissue
[29] data sets were accessed using the Oncomine database. Cancer
and normal tissue types are defined in Table W3. For the assess-
ment of prostate cell type expression, the Prostate cell-specific expres-
sion Affymetrix data set of Oudes et al. [30] was downloaded from
the Gene Expression Omnibus (GSE3998). Data are reported as
RMA-normalized fluorescent intensities.
Quantitative PCR
Quantitative PCR was performed using Power SYBRGreen Master-
mix (Applied Biosystems, Foster City, CA) on an Applied Biosystems
7300 Real Time PCR system as described [1,2]. All oligonucleotide
primers were synthesized by Integrated DNATechnologies (Coralville,
IA) and are listed in Table W2. All reactions were performed in dupli-
cate unless otherwise indicated.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed according
to published protocols using anti-ERG (sc-354x; Santa Cruz) or rab-
bit anti-IgG (sc-2027; Santa Cruz) antibodies [31]. For PCR analysis
of enrichment of target gene promoters, 2 μl each of input DNA,
ERG-enriched, or IgG-enriched DNA were subjected to PCR using
Platinum PCR Supermix (Invitrogen) and primers specific for target
gene promoters (Table W2).
Results
Transgenic Expression of ERG in the Mouse Prostate
Induces mPIN
Fusion transcripts juxtaposing exon 1 of TMPRSS2 (NM_005656.2)
to exon 2 of ERG isoform 1 (NM_182918.2; identical to exon 4 of
ERG isoform 2, NM_004449.3) are the most commonly detected tran-
scripts in TMPRSS2–ERG–positive cases (TMPRSS2–ERGa) [2,5,9].
Because exon 1 of TMPRSS2 is entirely noncoding, this fusion tran-
script likely results in a truncated ERG protein product. Thus, we gen-
erated transgenic mice expressing the truncated ERG product from
TMPRSS2–ERGa (beginning at exon 2 through the reported stop
codon (base 1533) of NM_182918.2, C-terminal FLAG-tagged) under
the control of the modified probasin promoter (ARR2Pb-ERG) (Fig-
ure 1a), which drives androgen-regulated transgene expression exclusively
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in the prostate [23,24]. This transgene is functionally analogous to the
TMPRSS2–ERGa fusion product. We obtained multiple ARR2Pb-ERG
founders and lines were expanded for phenotypic analysis. By 12 to
14 weeks of age, three of eight (37.5%) ARR2Pb-ERG mice developed
mPIN (Table W1 and Figure 1), the candidate precursor lesion of pros-
tate cancer [25].
We observed normal glands in the prostates of ARR2Pb-ERG
mice containing focal proliferative lesions displaying nuclear atypia,
including stratification, hyperchromasia, and macronucleoli (Fig-
ure 1, b–d ), consistent with the definition of mPIN [25]. In 12-
to 14-week-old ARR2Pb-ERG mice, foci of mPIN were observed
exclusively in the ventral lobe (Table W1). Immunohistochemistry
in ARR2Pb-ERG mice demonstrated strong ERG-FLAG expression
primarily in mPIN foci and not benign glands (Figure W1, a and b),
and qPCR confirmed that transgene expression was limited to the
prostate (data not shown).
Figure 1. Transgenic mice recapitulating TMPRSS2–ERG in the prostate develop mPIN. (a) To recapitulate TMPRSS2–ERG in vivo, we
generated transgenic mice over-expressing the ERG gene fusion product (exons 2 through the reported stop codon; 1533 of
NM_182918.2, C-terminal 3X-FLAG epitope tag) with a bovine growth hormone polyA signal (PA-BGH) under the control of the enhanced
probasin promoter (ARR2Pb). Mice were sacrificed at 12 to 14 weeks or >20 weeks, and mouse prostatic intraepithelial neoplasia
(mPIN) was observed in 4 of 11 ARR2Pb-ERGmice as described in Table W1. Benign epithelia and areas of mPIN are indicated by yellow
and black arrows, respectively. (b–d) Hematoxylin and eosin staining of ARR2Pb-ERG prostates for morphologic assessment. Consistent
with the focality of mPIN, (b) benign glands and (c and d) mPIN were observed in the ventral prostate (VP) of ARR2Pb-ERGmice. Original
magnification: (b) ×400, (c) ×200, and (d) inset showing area of mPIN with macronucleoli, ×400.
Figure 2. Over-expression of ERG in RWPE cells increases invasion through the plasminogen activator pathway. (a) To recapitulate
TMPRSS2–ERG in vitro, we generated adenoviruses and lentiviruses expressing the ERG gene fusion product (exons 2 through the
reported stop codon). (b and c) Infected (b) RWPE and (c) PrEC cells as indicated were assayed for invasion through a modified base-
ment membrane. Photomicrographs of invaded cells are shown below. (d) RWPE-ERG and RWPE-GUS (control vector) cells were pro-
filed on Agilent Whole Genome microarrays and expression signatures were loaded into the Oncomine Concept Map. Molecular
concept map analysis of the over-expressed in RWPE-ERG compared to RWPE-GUS signature (ringed yellow node). Each node repre-
sents a molecular concept, or set of biologically related genes. The node size is proportional to the number of genes in the concept. The
concept color indicates the concept type according to the legend. Each edge represents a significant enrichment (P < .005). (e) qPCR
confirmation of increased expression of genes involved in invasion. The amount of the indicated gene (normalized to the average of
GAPDH and HMBS) in RWPE-GUS (white) and RWPE-ERG (black) is shown. Inset shows immunoblot confirmation of increased expres-
sion of PLAU and MMP3 in RWPE-ERG cells. (f) Chromatin immunoprecipitation shows enrichment of ERG binding to the proximal
promoters of PLAU and MMP3 compared to IgG control. The promoter of KIAA0089 was used as a negative control. (g) RWPE-ERG
cells were treated with PLAU inhibitors amiloride or ectopic PAI-1, MMP inhibitors (including the pan-MMP inhibitor GM-6001), or the
EWS:FLI inhibitor ARA-C (EWS:FLI inhibitor) as indicated and assayed for invasion as in c. (h) RWPE-ERG cells were treated with trans-
fection reagent alone (untreated), or transfected with nontargeting, PLAU or PLAT siRNA as indicated and assayed for invasion through a
modified basement membrane. For all invasion assays, mean (n = 3) ± SEM are shown; *P < .05.
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All lesions were confirmed to be in situ by the presence of an intact
fibromuscular layer, as demonstrated by contiguous smooth muscle
actin staining (Figure W1, c and d ). However, immunohistochem-
istry with the basal cell marker p63 demonstrated loss of the circum-
ferential basal epithelial layer in ARR2Pb-ERG mPIN compared to
benign glands (Figure W1, e and f ), indicating the disruption of the
basal cell layer. Because loss of the basal layer is a hallmark of prostate
carcinoma development in both mice and humans [32], ARR2Pb-
ERG mice will be closely monitored for the development of invasive
carcinoma at later time points. Whereas we have not observed pro-
gression to invasive carcinoma in ARR2Pb-ERG mice, we have only
characterized three mice at greater than 20 weeks of age, one of
which (33.3%) also had mPIN in both the ventral and dorsolateral
lobes (Table W1). These results demonstrate that, although ERG
induces a neoplastic phenotype in the mouse prostate, providing sup-
port for an oncogenic role in human prostate cancer, it is not suffi-
cient for the development of prostate cancer in mice.
ERG Over-expression Induces an Invasion Program
In Vitro
Next, we determined the effects of ERG over-expression in vitro,
by generating adenoviruses and lentiviruses that express the same
truncated ERG product from TMPRSS2–ERGa as in the ARR2Pb-
ERG mice (Figure 2a). We infected the benign immortalized prostate
epithelial cell line RWPE with lentivirus expressing ERG and selected
for stable RWPE-ERG cells, and transiently over-expressed ERG in
primary benign prostate epithelial cells (PrEC) by infection with ad-
enovirus expressing ERG. By immunoblot analysis, we confirmed the
expression of a protein product recognized by a commercial anti–
ERG antibody in both RWPE and PrEC (Figure W2).
In both RWPE and PrEC cells, over-expression of ERG did not
increase proliferation (Figure W2), and ERG did not affect the per-
centage of RWPE cells in S phase by cell cycle analysis (Figure W2c).
Additionally, soft agar transformation assays showed that ERG over-
expression was not sufficient to transform RWPE cells (Figure W2d ).
Finally, orthotopic xenograft assays using RWPE-ERG cells did not
result in tumor formation (data not shown). However, ERG over-
expression markedly increased invasion in a modified basement mem-
brane invasion assay in both RWPE (5-fold, P = .001) (Figure 2b) and
PrEC cells (6.9-fold, P = .0016) (Figure 2c). Transient over-expression
of ERG in RWPE using ERG adenovirus similarly increased invasion
(Figure W3). These results are similar to over-expression of ETV1
and ETV5, which we have previously shown to increase invasion in
PrEC and RWPE cells [3,22].
To investigate the transcriptional program regulated by ERG, we
profiled stable RWPE-ERG and transiently expressing RWPE-ERG
and PrEC-ERG cells using Agilent Whole Genome Oligo Expression
Arrays, and identified 865, 854, and 221 features that were over-
expressed in the respective cell lines (as described in the Materials
and Methods section). We have recently developed a resource termed
the Oncomine Concepts Map (OCM, www.oncomine.org) to look
for associations between more than 20,000 biologically related gene
sets by disproportionate overlap [28,33]. Thus, we uploaded these
expression signatures into the OCM to identify transcriptional pro-
grams induced by ERG. We began by seeding the OCM analysis with
the over-expressed in stable RWPE-ERG signature. OCM analysis
identified the most significantly enriched concept as our previous
over-expressed in stable RWPE-ETV1 signature [22] [odds ratio
(OR) = 59.43, P = 1 × 10−100] (Figure 2d ), consistent with their
similar phenotypes and supporting the functional redundancy of
these ETS family members in gene fusions.
The stable RWPE-ERG signature also shared significant enrichment
with the over-expressed in transient RWPE-ETV5 (OR = 3.9, P = 1.2 ×
10−9), over-expressed in transient RWPE-ERG (OR = 19.43, P = 1.1 ×
10−100), and transient PrEC-ERG (OR = 5.77, P = 3.1 × 10−10) sig-
natures, demonstrating similarities in these transcriptional programs, as
well as several molecular concepts related to invasion. These concepts
include the Interpro concept of gene products containing Peptidase
M10A and M12B, matrixin or adamalysin domains (OR = 5.27, P =
.002), which includes MMPs and a disintegrin and metalloproteinase
domains (ADAM), and a signature of genes over-expressed in benign
breast epithelial cells (HMLHT) over-expressing the STAT3-C oncogene
(OR = 4.04, P = 6.3 × 10−5). In this system, STAT3-C over-expression
did not increase proliferation, but increased invasion in an MMP9-
dependent manner [34].
ERG-Mediated Induction of the Plasminogen
Activator Pathway
We identified several genes over-expressed in RWPE-ERG that were
present in multiple concepts in this enrichment network and have been
directly implicated in the invasion in multiple cancers and models, in-
cluding the metalloproteinases MMP3, MMP9, and ADAM19, the
urokinase plasminogen activator (PLAU), and the plasminogen acti-
vator inhibitor type 1 (SERPINE1, also known as PAI-1) [35,36]. Both
MMPs and the urokinase plasminogen pathway have been reported
to be direct targets of ETS transcription factors [35–37]. By qPCR,
we confirmed the over-expression of these genes, as well as the
MMP cleavage target IGFBP3 in RWPE-ERG cells (Figure 2e).
Figure 3. Knockdown of ERG in VCaP cells attenuates a transcriptional program over-expressed in TMPRSS2–ETS–positive prostate
cancers. (a) SiRNA knockdown of ERG in the TMPRSS2–ERG–positive prostate cancer cell line VCaP. VCaP cells were treated with trans-
fection reagent alone (untreated), or transfected with nontargeting or ERG siRNA (VCaP-siERG) as indicated. ERG knockdown was con-
firmed by immunoblot analysis. (b) VCaP cells as indicated were assayed for invasion through a modified basement membrane. (c)
VCaP-siERG and VCaP cells treated with nontargeting siRNA were profiled and a molecular concept map of the under-expressed in
VCaP-siERG signature (ringed yellow node) was generated. Each edge represents a significant enrichment (P < .001). Blue edges indi-
cate enrichments with in vivo ETS–positive versus negative prostate cancer signatures. (d) Chromatin immunoprecipitation identifies
PLAT and PLAU as direct targets of ERG in VCaP cells, by enrichment of ERG binding to the proximal promoters of PLAT and PLAU
compared to IgG control. The promoter of KIAA0089 was used as a negative control. (e) VCaP cells were treated with the indicated
inhibitors (as in Figure 2g) and assessed for invasion. (f) VCaP cells were treated with transfection reagent alone (untreated), or trans-
fected with nontargeting, PLAU or PLAT siRNA as indicated and assayed for invasion. For all invasion assays, mean (n = 3) ± SEM are
shown; *P < .05.
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By immunoblot analysis, we confirmed the over-expression of
PLAU and MMP3 in RWPE-ERG cells (Figure 2e). To determine if
these genes are direct targets of ERG, we performed ChIP, which dem-
onstrated that ERG binds to the proximal promoter of both PLAU and
MMP3 (Figure 2f ). No enrichment of ERG binding was observed in
RWPE-GUS cells or LNCaP (ETV1 rearrangement–positive [22]) for
MMP3 or PLAU (Figure W4).
We next assessed the role of both MMPs and the plasminogen ac-
tivator pathways in the invasive phenotype of RWPE-ERG cells using
small molecule MMP inhibitors, amiloride (a specific PLAU inhibi-
tor [38]), ectopic PAI-1 (which inhibits plasminogen activators [39])
and siRNA knockdown of PLAU. As shown in Figure 2g, whereas
MMP inhibitors did not significantly inhibit invasion, both amilor-
ide and PAI-1 significantly inhibited the invasiveness of RWPE-ERG
cells. Similarly, siRNA knockdown of PLAU significantly inhibited
the invasion of RWPE-ERG cells, whereas siRNA knockdown of
the tissue plasminogen activator (PLAT) had no effect on RWPE-
ERG invasion (Figure 2h). Similar effects on invasion were seen with
independent siRNA duplexes directed against PLAU. Cytosine arabi-
noside (ARA-C), which has recently been identified as an inhibitor of
the EWS–FLI fusion found in Ewing’s sarcoma [27], also showed no
effect on RWPE-ERG invasion (Figure 2g). Together, this work dem-
onstrates that ERG directly induces PLAU expression in RWPE cells
and that inhibition of PLAU blocks ERG-mediated invasion.
Knockdown of ERG in VCaP Cells Inhibits Invasion
Together, our in vivo and in vitro studies show that the most com-
mon TMPRSS2–ERG fusion product is unable to transform benign
prostatic epithelial cell lines or induce the development of frank ad-
enocarcinoma in the mouse prostate. However, our previous work,
including expression profiling on laser-captured microdissected cell
populations and a fluorescence in situ hybridization (FISH)–based
study on prostate cancer progression, suggest that TMPRSS2–ERG
gene fusions occur in the context of preexisting genetic lesions, often
during the PIN to carcinoma transition [7,33].
To investigate the role of TMPRSS2–ERG in this context of pre-
existing genetic lesions, we used siRNA to knockdown ERG in VCaP
(VCaP-siERG) cells that are known to harbor the TMPRSS2–ERG
gene fusion [2]. Immunoblot analysis confirmed that siRNA directed
against ERG reduced expression compared to nontargeting control
siRNA (Figure 3a). Quantitative PCR also demonstrated a 63% de-
crease in ERG transcript expression in VCaP-siERG (Figure W5a, P =
.009). ERG knockdown also significantly inhibited the invasion of
VCaP cells (Figure 3b) without affecting proliferation (Figure W5b),
similar to ERG over-expression in RWPE cells. Similar results were
seen using a second siRNA targeting an independent sequence in
ERG (data not shown).
To determine the transcriptional profile mediated by TMPRSS2–
ERG in VCaP, we profiled VCaP-siERG cells. We identified 265 and
291 features over- and under-expressed (as described in the Materials
and Methods section), respectively, in VCaP-siERG compared to
VCaP treated with nontargeting siRNA, and uploaded these signa-
tures into the OCM. The two most significantly enriched concepts
in our under-expressed in VCaP-siERG signature were two signatures
of genes over-expressed in ETS-positive versus -negative prostate cancers
(GSE8218, OR = 5.73, P = 2.5 × 10−19 and Vanaja et al. [40], OR =
3.49, P = 3.9 × 10−11) (Figure 3c). All other over-expressed in ETS-
positive versus -negative prostate cancer signatures [33,41,42] in the
Oncomine database were also enriched in our under-expressed in
VCaP-siERG signature, supporting VCaP as a highly relevant model
of TMPRSS2–ERG–positive prostate cancers. Our under-expressed
in VCaP-siERG signature also shared enrichment with our previous
signature of genes over-expressed in laser-captured prostate cancer versus
PIN (OR = 3.79, P = 4.5 × 10−6). In that study, we observed that
PIN and prostate cancer had very similar expression signatures and
hypothesized that TMPRSS2–ERG fusions occurred during the PIN
to prostate cancer transition and dysregulated a limited number of
transcripts, likely involved in invasion [33].
The Role of the Plasminogen Activator Pathway in VCaP Cells
Our under-expressed in VCaP-siERG signature also shared signif-
icant enrichment with our over-expressed in transient PrEC-ERG and
transient RWPE-ERG signatures (Figure 3c; OR = 6.89 and 3.21, P =
1.4 × 10−5 and 7 × 10−5, respectively), suggesting common transcrip-
tional programs controlled by ERG across cell types and genetic con-
text. Interestingly, although PLAU was not significantly dysregulated
in VCaP-siERG cells, the most strongly down regulated feature in
VCaP-siERG cells was tissue plasminogen activator (PLAT ). Similar
to PLAU, which we showed to be strongly over-expressed and a di-
rect target of ERG in RWPE cells, we confirmed that PLAT was
strongly downregulated (Figure W5c). Quantitative PCR analysis
showed that VCaP-siERG cells expressed very low levels of PLAU
at baseline (Figure W6), however ChIP identified both PLAU and
PLAT as direct targets of ERG in VCaP-siERG cells (Figure 3d ).
Whereas ectopic PAI-1, amiloride (which inhibits PLAU but not
PLAT [38]) (Figure 3e), and siRNA knockdown of PLAU inhibited
the invasion of VCaP cells, siRNA knockdown of PLAT had no effect
on VCaP invasion (Figure 3f ). Additionally, inhibitors of MMPs and
ARA-C had no significant effect on VCaP invasion (Figure 3e), sim-
ilar to RWPE-ERG. Together, these results support plasminogen ac-
tivators as direct targets of ERG across multiple TMPRSS2–ERG
model systems and demonstrate that inhibition of PLAU blocks
ERG-induced invasion across TMPRSS2–ERG cell line models.
Figure 4. ERG knockdown in VCaP cells derepresses a transcriptional program associated with normal prostatic epithelial cell differen-
tiation. (a) VCaP-siERG and VCaP cells treated with nontargeting siRNA were profiled and a molecular concept map of the over-
expressed in VCaP-siERG signature (ringed yellow node) was generated. Each edge represents a significant enrichment (P < .001). Blue
edges indicate enrichments with in vivo ETS-positive versus -negative prostate cancer signatures. (b) Overlay map identifying genes
present (red cells), including KLK3 (PSA), across multiple concepts in the over-expressed in VCaP-siERG enrichment network (indicated
by number). (c) qPCR confirmation of increased expression in VCaP-siERG cells (black) compared to VCaP-NT cells (white) of transcripts
strongly expressed in prostatic epithelial cells. (d) Analysis of prostate cell type specificity using a microarray data set profiling magnet-
ically sorted prostate cell populations. Mean RMA normalized fluorescent intensities (n = 5 ± SEM) are shown. *P < .05, for all pairwise
t tests involving luminal cells.
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Transcriptional Signatures of ERG in VCaP Cells
Our under-expressed in VCaP-siERG signature also shared significant
enrichment with a cluster of 18 genes coexpressed across 72 prostate
cancer tissue samples [41], with eight genes shared (OR = 56.65, P =
7.2 × 10−10). Because this cluster contains ERG (Figure W5d ), this
result supports ERG knockdown in VCaP-modulating genes regulated
by ERG in TMPRSS2–ERG–positive tumors. To identify such genes,
we examined genes coexpressed with ERG across multiple prostate
cancer profiling studies in the Oncomine database. We identified four
genes, CACNA1D, KCNS3, LAMC2, and PLA1A, that were down-
regulated in VCaP-siERG cells and also showed greater than 0.5 cor-
relation with ERG across multiple prostate cancer profiling studies
(Figure W7). CACNA1D was significantly down regulated in three
of four arrays, with the fourth array showing 0.54-fold expression in
VCaP-siERG (P = .06). In addition, we also identified decreased ex-
pression of ARGHDIB in VCaP-siERG cells and over-expression in all
ETS-positive versus -negative expression signatures (Figure W5d ). By
qPCR, we confirmed the decreased expression of these genes in VCaP-
siERG cells (Figure W5e) and ChIP identified LAMC2, KCNS3, and
PLA1A as direct targets of ERG (Figure W5f). By qPCR, we also con-
firmed the coexpression of ERG and PLA1A (R = 0.72, P = 6.1 × 10−8)
in an independent set of prostate tissues (Figure W5g). Thus, our work
provides direct ERG target genes over-expressed in TMPRSS2–ERG–
positive prostate cancers for further functional study.
We next examined our over-expressed in VCaP-siERG signature using
the OCM. Consistent with the results described above, all under-
expressed in ETS-positive versus -negative prostate cancer signatures in
the Oncomine database (GSE8218 and [33,40–42]) were enriched
in our over-expressed in VCaP-siERG signature (OR = 6.41–2.71, P =
5.2 × 10−15 to 7.0 × 10−5). Intriguingly, OCM analysis revealed that
the most significantly enriched concept in our over-expressed in VCaP-
siERG signature was a signature of genes over-expressed in prostate cancers
compared to 28 other cancer types (GSE2109) (OR = 4.46, P = 5.8 ×
10−18) (Figure 4a). Several other concepts representing genes over-
expressed in prostate cancer compared to other cancers, normal prostate
tissue compared to other normal tissues and normal prostate compared
to prostate cancer were also strongly enriched in our signature. Exam-
ining the genes common to these concepts and VCaP-siERG, we iden-
tified numerous archetypal prostate epithelial cell transcripts, including
KLK3 (PSA), MSMB, NKX3-1, TMPRSS2, TRGV9 (also known as
TARP) [43], SLC30A4 (also known as ZnT4) [44], and SLC45A3
[22] (Figure 4b and Figure W8). We confirmed the over-expression
of this transcriptional program by qPCR (Figure 4c), and confirmed
that these genes are normally expressed specifically in luminal epithelial
prostate cells using an independent data set containing expression pro-
filing data from magnetically sorted prostate luminal epithelial, basal
epithelial, stromal fibromuscular, and endothelial cells (Figure 4d and
Figure W8). Because ERG knockdown in VCaP results in the increased
expression of genes associated with differentiated luminal prostate epi-
thelial cells, we hypothesize that TMPRSS2–ERG fusion may function
to keep prostate cancer cells in a dedifferentiated state. Future experi-
ments will be needed to address this hypothesis.
Discussion
Our in vitro and in vivo studies on the TMPRSS2–ERG fusion
described here support the functional similarity between ETS gene
fusions, consistent with our initial observation of mutually exclusive
ERG or ETV1 over-expression in prostate cancers [2]. This includes
the similar phenotypic and transcriptional programs induced by
ERG, ETV1, and ETV5 over-expression in benign prostate cells,
the similar phenotype of transgenic mice expressing ERG or ETV1
in the prostate [22], and the enrichment of genes over-expressed in
ERG or ETV1-positive versus ETS-negative prostate cancers in our
VCaP-siERG signature (see Figure 3c).
Importantly, our in vivo and in vitro studies show that the most
common TMPRSS2–ERG fusion product is unable to transform be-
nign prostatic epithelial cell lines or induce the development of frank
adenocarcinoma in the mouse prostate. However, both of these re-
sults are consistent with the occurrence of TMPRSS2–ERG fusions in
the context of preexisting genetic lesions during the course of human
prostate cancer development.
Similar to the expression of the TMPRSS2–ETV1 fusion product
in the mouse prostate [22], expression of the TMPRSS2–ERG fusion
product in the mouse prostate resulted in the development of PIN,
without the development of frank adenocarcinoma. As described be-
low, in human prostate cancer development, TMPRSS2–ERG fusions
occur in the context of earlier lesions, such as loss of single NKX3-1
and/or PTEN alleles [45]. Importantly, mouse models of such early
lesions, such as NKX3-1+/− and PTEN +/− mice [46–48], also only de-
velop mPIN without frank adenocarcinoma. Together, these results
are consistent with the development of invasive prostate cancer re-
quiring multiple genetic lesions. Importantly, these results also sug-
gest that crosses between ARR2Pb-ERG mice and transgenic mice
modeling earlier lesions should produce highly relevant oncogene/
tumor suppressor models mimicking early events in human prostate
cancer development.
In this study, over-expression of ERG in benign prostate cells
markedly increased invasion but did not result in transformation,
similar to experiments with ETV1 and ETV5 [3,33]. These results
support our previous hypothesis that ETS gene rearrangements me-
diate invasion in human prostate cancer development. For example,
using expression profiling on laser captured microdissected cell popu-
lations, we demonstrated that whereas benign prostatic epithelial cells
and epithelial cells in PIN lesions have distinct expression profiles,
PIN and cancerous epithelium share remarkably similar expression
profiles [33]. This suggests that PIN and cancerous cells share many
genetic lesions, with a limited number of genetic events likely medi-
ating the PIN to prostate cancer transition (defined histologically by
the presence of invasion). Importantly in our profiled samples,
TMPRSS2–ERG fusions only occurred in prostate cancer and not
in PIN lesions (as evidenced by ERG outlier expression), suggesting
that it might be the key lesion driving the invasive transition.
Further supporting a role for TMPRSS2–ERG in invasion, we pre-
viously demonstrated in a FISH-based study that TMPRSS2–ERG
fusion was not identified in benign prostate cells or proliferative in-
flammatory atrophy, which may be an early precursor of PIN/prostate
cancer. However, TMPRSS2–ERG fusion could be detected in 19% of
PIN lesions, but these foci were intermingling with cancerous glands
that were similarly TMPRSS2–ERG–positive [7]. TMPRSS2–ERG
fusion was not identified in PIN lesions distant to prostate cancer, even
if the cancerous lesion from the same individual demonstrated the
TMPRSS2–ERG fusion. Together, this FISH-based study suggested
that TMPRSS2–ERG fusions may directly mediate the development
of prostate cancer from PIN lesions.
Thus, to study TMPRSS2–ERG function in a more realistic cel-
lular context, we investigated the effects of ERG knockdown in the
TMPRSS2–ERG–positive VCaP cell line. These experiments con-
firmed VCaP as a highly relevant prostate cancer cell line model,
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as siRNA knockdown of ERG inhibited invasion and modulated
transcriptional programs activated in TMPRSS2–ERG–positive tu-
mors. Additionally, ERG knockdown also modulated the transcrip-
tional program that differentiated our laser captured PIN and
prostate cancer cell populations, consistent with TMPRSS2–ERG
driving this important transition. Importantly, these programs were
not modulated by ERG over-expression in RWPE cells, further sup-
porting VCaP as a more realistic model of TMPRSS2–ERG prostate
cancer. Interestingly, in both RWPE-ERG and VCaP cells, we dem-
onstrate that the plasminogen activator pathway is crucial to ERG-
mediated invasion, similar to ETV5-mediated invasion [3]. Thus,
this pathway warrants further investigation as a therapeutic target
for TMPRSS2–ERG–positive prostate cancer.
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Table W1. Prostate Pathology in ARR2Pb-ERG Transgenic Mice.
ARR2Pb-ERG Mouse Founder No. Age AP VP DLP Diagnosis Liver
1 272 12 weeks Normal Hyperplasia Normal Hyperplasia NA
2 272 12 weeks Normal Hyperplasia Adipose tissue Hyperplasia NA
3 285 12 weeks Normal mPIN Normal mPIN NA
4 285 12 weeks Normal mPIN Hyperplasia mPIN Normal
5 429 12–14 weeks Hyperplasia Hyperplasia Hyperplasia Hyperplasia Normal
6 429 12–14 weeks Normal No tissue Hyperplasia Hyperplasia Normal
7 429 12–14 weeks No tissue mPIN Normal mPIN NA
8 457 12–14 weeks Normal Hyperplasia Normal Hyperplasia Normal
9 285 20 weeks Normal Hyperplasia Hyperplasia Hyperplasia Normal
10 282 34 weeks Hyperplasia mPIN mPIN mPIN Normal
11 302 15 months Hyperplasia Hyperplasia Hyperplasia Hyperplasia Normal
Total: 0/10 (0%) 4/10 (40%) 1/11 (9.1%) 4/11 (36.3%)
For ARR2Pb-ERG transgenic mice, the founder number is indicated, along with the age of sacrifice. Observed pathology from H&E–stained sections from the anterior (AP), ventral (VP), and dorsolat-
eral (DLP) prostatic lobes and an overall diagnosis of prostate pathology are given. The liver from the indicated mice was also dissected, and H&E–stained sections were observed for any pathology.
NA, not available.
Table W2. Oligonucleotide Primers.
Assay Gene/Region Sequence Bases Primer Sequence 5′ to 3′
Expression qPCR ERG NM_004449.3 574–597 ERG_exon 5–6_f CGCAGAGTTATCGTGCCAGCAGAT
Expression qPCR ERG NM_004449.3 659–636 ERG_exon 5–6_r CCATATTCTTTCACCGCCCACTCC
Expression qPCR SERPINE1 NM_000602.1 1181–1200 SERPINE1-f GCATGGCCCCCGAGGAGAT
Expression qPCR SERPINE1 NM_000602.1 1270–1248 SERPINE1-r CTTGGCCCATGAAAAGGACTGTT
Expression qPCR IGFBP3 NM_000598.4 738–762 IGFBP3-f CGAGTCCAAGCGGGAGACAGAATA
Expression qPCR IGFBP3 NM_000598.4 837–814 IGFBP3-r TACACCCCTGGGACTCAGCACATT
Expression qPCR MMP3 NM_002422.3 1055–1080 MMP3-f TTCATTTTGGCCATCTCTTCCTTCAG
Expression qPCR MMP3 NM_002422.3 1181–1155 MMP3-r TATCCAGCTCGTACCTCATTTCCTCT
Expression qPCR ADAM19 NM_023038.3 2146–2165 ADAM19-f GCCTATGCCCCCTGAGAGTG
Expression qPCR ADAM19 NM_023038.3 2271–2245 ADAM19-r GCTTGAGTTGGCCTAGTTTGTTGTTC
Expression qPCR MMP9 NM_004994.2 1181–1201 MMP9-f TGCCCGGACCAAGGATACAGT
Expression qPCR MMP9 NM_004994.2 1239–1221 MMP9-r AGCGCGTGGCCGAACTCAT
Expression qPCR PLAU NM_002658.2 1169–1194 PLAU-f TACGGCTCTGAAGTCACCACCAAAAT
Expression qPCR PLAU NM_002658.2 1308–1286 PLAU-r CCCCAGCTCACAATTCCAGTCAA
Expression qPCR ARHGDIB NM_001175.4 250–273 ARHGDIB-f AGAAAACGCTGCTGGGAGATGGT
Expression qPCR ARHGDIB NM_001175.4 326–307 ARHGDIB-r CAGGGTGAGCCGGGTGACAA
Expression qPCR KCNS3 NM_002252.3 1576–1599 KCNS3-f CCCTTCCCATCACCATCATCTTCA
Expression qPCR KCNS3 NM_002252.3 1659–1635 KCNS3-r CCTCACTGCACTGGTCCACATCAAT
Expression qPCR LAMC2 NM_005562.1 3317–3345 LAMC2-f GGTGATTACAGAAGCCCAGAAGGTTGATA
Expression qPCR LAMC2 NM_005562.1 3408–3385 LAMC2-r GCAGGAGGCCGTCTAATGTGTTGA
Expression qPCR F5 NM_000130.4 6560–6583 F5-f CAGGGCTGCAAGTCTCTGTCCTCT
Expression qPCR F5 NM_000130.4 6641–6617 F5-r GTTTCCATTCCACTCCCTGCTCACT
Expression qPCR CACNA1D NM_000720.1 5776–5805 CACNA1D-f CTACTACAGCAGATACCCAGGCAGAAACAT
Expression qPCR CACNA1D NM_000720.1 5885–5861 CACNA1D-r GTGAATCATAGCAAACGGGCGAGTC
Expression qPCR CD44 NM_000610.3 3702–3727 CD44-f TGTTATCCCTGGGGCCCTATTTCAT
Expression qPCR CD44 NM_000610.3 3820–3791 CD44-r ATCTCTTTCATTTCCATTGGCTTCTTCTCT
Expression qPCR PLAU NM_002658.2 1169–1194 PLAU-f TACGGCTCTGAAGTCACCACCAAAAT
Expression qPCR PLAU NM_002658.2 1308–1286 PLAU-r CCCCAGCTCACAATTCCAGTCAA
Expression qPCR PLA1A NM_015900.1 1194–1216 PLA1A-f CCACCCCACAATGCCAGATAAAC
Expression qPCR PLA1A NM_015900.1 1283–1258 PLA1A-r TCCCAATAATGGTAGTCCGGTCTTTT
Expression qPCR PLAT NM_033011.1 843–863 PLAT-f CACTGGGCCTGGGCAAACATA
Expression qPCR PLAT NM_033011.1 933–913 PLAT-r CACGTCAGCCTGCGGTTCTTC
Expression qPCR KLK3 NM_001648.2 826–849 KLK3-f GAGCACCCCTATCAACCCCCTATT
Expression qPCR KLK3 NM_001648.2 944–921 KLK3-r AGCAACCCTGGACCTCACACCTAA
Expression qPCR SLC30A4 NM_013309.4 1608–1637 SLC30A4-f TGTATTTTGGGAACTCCTGCCTTATTTATC
Expression qPCR SLC30A4 NM_013309.4 1696–1668 SLC30A4-r CAGGGATTCCATTTTCTCATTTAGGTTTG
Expression qPCR SLC45A3 NM_033102.2 1223–1242 SLC45A3-f TCGTGGGCGAGGGGCTGTA
Expression qPCR SLC45A3 NM_033102.2 1308–1284 SLC45A3-r CATCCGAACGCCTTCATCATAGTGT
Expression qPCR TMPRSS2 NM_005656.2 1539–1563 TMPRSS2-f CAGGAGTGTACGGGAATGTGATGGT
Expression qPCR TMPRSS2 NM_005656.2 1608–1585 TMPRSS2-r GATTAGCCGTCTGCCCTCATTTGT
Assay Gene Location (to TSS) Predicted ETS Site Primer Sequence
ChIP PCR PLAU −1458 −1410 & 135 PLAU_pF2 ATTTGCAAGGCAGGAAAATG
ChIP PCR PLAU −1282 PLAU_pR2 GTGATTCTGTCACCCCCATC
ChIP PCR PLAT −217 −57 PLAT_pF1 TGTCATCACAGGGTCCTGAA
ChIP PCR PLAT −27 PLAT_pR1 TAAAGCAGGGGGAGGAAGTT
ChIP PCR MMP3 −227 −223 MMP3_pF1 CCTCTACCAAGACAGGAAGCA
ChIP PCR MMP3 −93 MMP3_pF1 GCAGGACCATTTCCAAACAT
ChIP PCR PLA1A −287 −246 PLA1A_pF1 TATCACGGGAAGTGGGAGAG
ChIP PCR PLA1A −143 PLA1A_pR1 TGCCAGAGTTTTCGGTTTCT
ChIP PCR LAMC2 −561 −535 LAMC2_pF1 CCCTGGTGAGCAGGAAGTTA
ChIP PCR LAMC2 −474 LAMC2_pR1 CACCCTCCAGTTTAGGGTCA
ChIP PCR KCNS3 −1325 −1144 KCNS3_pF1 TAGCCTCTCCTCTGGACCAA
ChIP PCR KCNS3 −1083 KCNS3_pR1 GCAGATTCAAGCTCCAGACC
ChIP PCR ARHGDIB −1692 −1733 ARHGDIB_pF1 TGCTCTCTCATCCCCCAATA
ChIP PCR ARHGDIB −1604 ARHGDIB_pR1 CACCCCTTCCCAGAAAAATC
ChIP PCR KIAA0079 Within exon 23 NA KIAA0079_Exon23 TCTGTCATGTCCTGCTGATGGA
ChIP PCR KIAA0079 Within exon 23 KIAA0079_Exon23 GCCCAAGAAGGACTGACCACTT
Oligonucleotide primers for all assays described in the Materials and Methods section are listed. The assayed gene expression qPCR for all primers is indicated, along with the bases from the
corresponding GenBank sequence. All primers are listed 5′ to 3′. For primers for ChIP PCR, the gene, primer location (in relation to the transcriptional start site (TSS)), and the location of predicted
ETS binding sites (in relation to the TSS) are given.
Table W2. (continued )
Table W3. Cancer Types and Normal Tissues from the expO and Shyamsundar Normal Tissue Datasets.
International Genomics Consortium’s expO Data Set (GSE2109) (Bittner_Multi-cancer
at www.oncomine.org)
Shyamsundar Normal Tissue Data Set (GSE2193) (Shyamsundar_Normal
at www.oncomine.org)
No. Cancer Type n No. Normal Tissue Type n
1 Bladder papillary carcinoma 4 1 Adrenal 4
2 Bladder transitional cell carcinoma 10 2 Bladder 2
3 Breast ductal carcinoma 95 3 Brain 8
4 Cervix squamous cell carcinoma 10 4 Buffycoat 2
5 Colon adenocarcinoma 104 5 Cervix 3
6 Metastatic colon carcinoma 16 6 Colon 3
7 Mucinous colon carcinoma 12 7 Esophagus 3
8 Endometrial adenocarcinoma 5 8 Fallopian tube 4
9 Endometrial endometrioid carcinoma 45 9 Heart 6
10 Endometrial mixed mullerian tumor 6 10 Kidney 5
11 Metastatic endometrial carcinoma 7 11 Liver 5
12 Soft tissue sarcoma 13 12 Lung 4
13 Clear cell renal carcinoma 78 13 Lymph node 5
14 Papillary renal cell carcinoma 6 14 Muscle 2
15 Lung adenocarcinoma 19 15 Ovary 5
16 Bronchioloalveolar carcinoma 7 16 Pancreas 2
17 Squamous cell lung carcinoma 17 17 Parathyroid 3
18 Ovarian adenocarcinoma 20 18 Salivary Gland 4
19 Ovarian endometrioid carcinoma 13 19 Seminal Vesicle 3
20 Metastatic ovarian carcinoma 36 20 Small Bowel 3
21 Ovarian mucinous carcinoma 4 21 Spleen 3
22 Ovarian papillary carcinoma 38 22 Stomach 4
23 Pancreatic ductal carcinoma 3 23 Testes 3
24 Rectosigmoid adenocarcinoma 15 24 Thymus 2
25 Rectal adenocarcinoma 13 25 Thyroid 6
26 Renal pelvis transitional cell carcinoma 4 26 Tonsil 4
27 Metastatic melanoma 5 27 Uterus 5
28 Papillary thyroid carcinoma 10 Prostate 5
Prostate adenocarcinoma 15
For the expO multicancer data set accessed in the Oncomine database, the 29 cancer types displayed in Figure W7 are indicated with the number of profiled samples per type. For the Shyamsundar
normal tissue data set, the 28 normal tissue types displayed in Figure W7 are indicated.
Figure W1. Development of mPIN in TMPRSS2–ERG transgenic mice. (a and b) Immunohistochemistry confirmed ERG-FLAG expression
exclusively in areas of mPIN and not benign glands in ARR2Pb-ERG mice. Benign epithelia and areas of mPIN are indicated by yellow
and black arrows, respectively. (c and d) Immunohistochemistry with smooth muscle actin (SMA) demonstrates a continuous fibromus-
cular layer around (c) benign glands and (d) all mPIN lesions, whereas the basal cell markers (e and f) p63 demonstrate loss of circum-
ferential basal cells in mPIN foci (f) compared to normal glands (e). Original magnification, ×400.
Figure W2. Over-expression of ERG does not affect proliferation or transform benign prostatic epithelial cells. (a) Primary prostatic ep-
ithelial cells (PrEC) were infected with ERG or LACZ adenovirus as indicated and assayed for proliferation. Mean (n = 3) ± SEM are
shown. Results are representative of three independent experiments. (b) The benign immortalized prostate cell line RWPE was infected
with ERG or control (GUS) lentivirus as indicated, and stable clones were generated and assayed for proliferation. Insets of a and b show
ERG over-expression by immunoblot analysis. (c) ERG over-expression does not increase the percentage of RWPE cells in S phase.
RWPE-GUS and RWPE-ERG cells were analyzed for cell cycle distribution by fluorescence activated cell sorting (FACS). The distributions
of cells in the G1, S, and G2 phases are indicated. Mean (n = 4) ± SEM are shown. (d) ERG over-expression does not enhance the
anchorage independent growth of RWPE cells. RWPE-GUS, RWPE-ERG, and DU145 (positive control) cells were assessed for anchorage-
independent growth by assaying colony formation in soft agar. After 12 days, the plates were stained, and colonies counted. The number of
colonies per high-power field was assessed. Mean colonies per field (n = 6) ± SEM are shown.
Figure W3. Transient over-expression of ERG increases invasion in RWPE cells. We infected the benign immortalized prostate cell line
RWPE with ERG or LACZ adenovirus and assayed for invasion through a modified basement membrane, mean (n = 3) ± SEM. Inset
shows photomicrograph of invaded cells.
Figure W4. Chromatin immunoprecipitation across TMPRSS2–ERG model systems. (a) Chromatin immunoprecipitation to detect enrich-
ment of ERG binding to the proximal promoters of indicated genes compared to IgG control in RWPE-ERG and VCaP cells. The promoter of
KIAA0089 was used as a negative control. (b) RWPE-GUS and LNCaP failed to show any enrichment of ERG binding to assayed promoters.
Figure W5. ERG knockdown in VCaP attenuates a transcriptional program over-expressed in TMPRSS2:ETS–positive tumors. (a) siRNA
knockdown of ERG in the TMPRSS2–ERG–positive prostate cancer cell line VCaP. VCaP cells were either treated with transfection re-
agent alone (untreated) or transfected with nontargeting or ERG siRNA (VCaP-siERG) as indicated. ERG knockdown was confirmed by
qPCR. (b) ERG knockdown in VCaP does not affect cell proliferation. VCaP cells as indicated were assayed for proliferation by cell count-
ing 72 hours after siRNA transfection. Mean (n = 3) ± SEM are shown. (c) qPCR confirmation of decreased PLAT expression in VCaP-
siERG compared to VCaP-siNT cells. (d) Overlay map identifying genes present (red cells) across multiple concepts in the VCaP-siERG
enrichment network (indicated by number). CACNA1D, in magenta, was identified as differentially expressed in three of four replicate
VCaP-siERG arrays. Genes confirmed as under-expressed in VCaP-siERG cells by qPCR are indicated in blue. (e) qPCR confirmation of
downregulated genes in VCaP-siERG cells; *P < .05, compared to VCaP treated with nontargeting siRNA. (f) Chromatin immunoprecip-
itation identification of direct ERG targets. (g) ERG and PLA1A show correlated expression across prostate tissues. ERG and PLA1A
expression (normalized to GAPDH) was determined by qPCR in benign prostate (green), localized prostate cancer (PCa, red), and meta-
static prostate cancer (Met PCa, black) tissue samples. The trend line is shown in blue.
Figure W6. qPCR confirmation of PLAU and PLAT knockdown in RWPE-ERG and VCaP cells. (a and b) RWPE-ERG cells were treated with
non-targeting siRNA or siRNA against (a) PLAU or (b) PLAT, and knockdown was confirmed by qPCR. (c and d) VCaP cells were treated
with nontargeting siRNA or siRNA against (c) PLAU or (d) PLAT, and knockdown was confirmed by qPCR. (e) The relative amount of PLAT
and PLAU in RWPE-ERG (white) compared to VCaP (black) was determined by qPCR.
Figure W7. Identification of genes showing coexpression with ERG across multiple prostate cancer profiling studies. Genes showing
coexpression with ERG (R > 0.5) from prostate cancer profiling studies in the Oncomine database. ERG was queried in the Oncomine
database using the coexpression module. For each study, all genes showing R > 0.5 are listed, along with the corresponding feature
identification. ERG is indicated in red. Genes showing R > 0.5 in multiple studies are indicated in blue.
Figure W8. Prostate epithelial specificity of genes induced in VCaP on ERG knockdown. (a) Genes confirmed by qPCR to be over-
expressed in VCaP cells treated with ERG siRNA were interrogated in the expO multicancer data set, containing expression profiles
from 28 cancer types (blue) and prostate cancer (magenta). The significance of prostate cancer versus all other cancer types is indicated.
(b) The same genes were also interrogated in the Shyamsundar et al. [29] normal tissue data set, containing expression profiles from
27 normal tissue types (blue) and normal prostate tissue (magenta). For both a and b, box and whisker plots show the median and 10th
and 90th percentiles in normalized expression units (z scores). All cancer and normal tissue types are defined in Table W3. (c) Analysis
of prostate cell type specificity using a microarray data set profiling magnetically sorted prostate cell populations for additional genes
identified as over-expressed in VCaP cells on ERG knockdown (see Figure 4b). Mean RMA–normalized fluorescent intensities (n = 5 ±
SEM) are shown. *P < .05, for all pairwise t tests involving luminal cells.
